Boston Scientific Co. (NYSE:BSX) Shares Bought by National Bank of Canada FI

National Bank of Canada FI increased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 51.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 666,891 shares of the medical equipment provider's stock after buying an additional 225,221 shares during the quarter. National Bank of Canada FI's holdings in Boston Scientific were worth $55,885,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Aspire Private Capital LLC raised its holdings in shares of Boston Scientific by 30.3% during the second quarter. Aspire Private Capital LLC now owns 11,568 shares of the medical equipment provider's stock worth $891,000 after purchasing an additional 2,687 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Boston Scientific by 6.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 26,295 shares of the medical equipment provider's stock valued at $2,025,000 after buying an additional 1,661 shares during the period. Voisard Asset Management Group Inc. boosted its stake in shares of Boston Scientific by 63.4% in the second quarter. Voisard Asset Management Group Inc. now owns 1,289 shares of the medical equipment provider's stock worth $99,000 after buying an additional 500 shares during the last quarter. Wedmont Private Capital grew its holdings in Boston Scientific by 15.0% during the second quarter. Wedmont Private Capital now owns 17,156 shares of the medical equipment provider's stock worth $1,333,000 after acquiring an additional 2,242 shares during the period. Finally, Meyer Handelman Co. purchased a new position in Boston Scientific during the second quarter valued at approximately $242,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on BSX. Morgan Stanley upped their price objective on Boston Scientific from $92.00 to $100.00 and gave the stock an "overweight" rating in a research report on Thursday, October 24th. Truist Financial raised their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Canaccord Genuity Group upped their price objective on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. BTIG Research increased their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Finally, Mizuho lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Boston Scientific presently has an average rating of "Moderate Buy" and an average price target of $93.39.

Boston Scientific Price Performance

Shares of BSX stock traded down $0.46 during trading hours on Friday, reaching $90.07. The company had a trading volume of 3,302,016 shares, compared to its average volume of 4,982,464. Boston Scientific Co. has a 12-month low of $54.52 and a 12-month high of $91.93. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a market capitalization of $132.75 billion, a price-to-earnings ratio of 74.44, a PEG ratio of 2.68 and a beta of 0.80. The stock has a fifty day moving average of $87.40 and a 200-day moving average of $81.34.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company had revenue of $4.21 billion during the quarter, compared to analysts' expectations of $4.04 billion. During the same period in the prior year, the business earned $0.50 EPS. The firm's quarterly revenue was up 19.3% on a year-over-year basis. On average, equities analysts anticipate that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the sale, the executive vice president now directly owns 34,748 shares in the company, valued at $2,913,967.28. This trade represents a 16.73 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares in the company, valued at approximately $87,306.06. This represents a 93.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 328,157 shares of company stock worth $27,957,676 in the last 90 days. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.